customized whole-genome high-density microarrays (Agendia BV)
90
Structured Review
Agendia BV
customized whole-genome high-density microarrays
Customized Whole Genome High Density Microarrays, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/snp+microarray+analysis+high-density+snp+array/44k+full+genome+microarray/pmc10216373-0-22-20
Average 90 stars, based on 1 article reviews
Customized Whole Genome High Density Microarrays, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/snp+microarray+analysis+high-density+snp+array/44k+full+genome+microarray/pmc10216373-0-22-20
Average 90 stars, based on 1 article reviews
customized whole-genome high-density microarrays - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management"
Article Title: Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management
Journal: Cancers
doi: 10.3390/cancers15102746
Figure Legend Snippet: Available gene expression assays predictive of prognosis in early-stage CRC.
Techniques Used: Gene Expression, Expressing, Formalin-fixed Paraffin-Embedded, Amplification, Microarray, Derivative Assay
Related Articles
other:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: Biomarker analyses were performed on pre-treatment biopsies, which included the Article Title: Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial — Efficacy and biomarker discovery Article Snippet: The Article Title: Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management Article Snippet: Article Title: Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer Article Snippet: Biomarker analyses were performed using Diagnostic Assay:Article Title: BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance. Article Snippet: Microarray processing was performed following standard procedure at Agendia [7] (Supplementary methods). .. Agendia’s customized diagnostic arrays were either a targeted array or a Isolation:Article Title: IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women Article Snippet: Estradiol measurements were performed using a second-generation Cobas Estradiol immunoassay, and run on a Cobas 6000 device from Roche Diagnostics, following the standard manufacturer’s instructions. .. RNA was isolated and hybridized to a Gene Expression:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. After the participant consents to be screened, a core biopsy will be performed, and sections will be sent to Agendia for MammaPrint score and TargetPrint HER2 gene expression assay using the Agendia Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and TargetPrint HER2 gene expression arrays using the 44 K Microarray:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. After the participant consents to be screened, a core biopsy will be performed, and sections will be sent to Agendia for MammaPrint score and TargetPrint HER2 gene expression assay using the Agendia Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and TargetPrint HER2 gene expression arrays using the 44 K Expressing:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and TargetPrint HER2 gene expression arrays using the 44 K Phospho-proteomics:Article Title: Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2 + breast cancer in the adaptively randomized I-SPY2 trial Article Snippet: .. Qualified, pre-specified biomarkers evaluated included MammaPrint and TargetPrint HER2 gene expression arrays using the 44 K |